Innovative Immunological and Target Therapies for NMIBC: Recent Clinical Trial Data Shaping the Future : Episode 8
Opinion
Video
Future of BCG in NMIBC
Author(s):
Panelists discuss how it would be preferred that BCG monotherapy not remain the first-line treatment for intermediate-risk and high-risk disease within the next 10 years. It is encouraged that the future of first-line treatment be a noninfectious agent that would be easier to develop and include more data.
Video Player is loading.
Video content above is prompted by the following:
- Given these recent advances and emerging agents, do you think BCG monotherapy will remain the first-line treatment for intermediate-risk and high-risk disease?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
RX Review: Implementing mitomycin for LG-IR-NMIBC in clinical practice
RX Review: TURBT vs chemoablation for low-grade, intermediate-risk NMIBC
RX Review: A paradigm shift for low-grade, intermediate-risk NMIBC
RX Review: How mitomycin for intravesical solution works in treating LG-IR-NMIBC
RX Review: Redefining treatment for LG-IR-NMIBC
Vignesh Packiam, MD, on the MOA, dosing of detalimogene voraplasmid
The Logistical Challenges in ccRCC Treatment
The Role of Genomic Classifiers in Guiding Therapy for Localized High-Risk Prostate Cancer
The Future of PET Imaging Agents
A 62-Year-Old Man With High-Risk Localized Prostate Cancer
Related Content
